Systematic (IUPAC) name | |
---|---|
2-[2-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl- | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Pregnancy cat. | ? |
Legal status | ? |
Identifiers | |
CAS number | 113662-23-0 |
ATC code | V08CA08 |
PubChem | CID 105124 |
ChemSpider | 94843 |
UNII | 15G12L5X8K |
KEGG | D08018 |
ChEMBL | CHEMBL1200571 |
Chemical data | |
Formula | C22H28GdN3O11 |
Mol. mass | 667.72 g/mol |
SMILES | eMolecules & PubChem |
|
|
(verify) |
(what is this?)
Gadobenic acid is a complex of gadolinium with the ligand BOPTA. In the form of the diglumine salt it functions as a gadolinium-based MRI contrast medium, under the trade name gadobenate dimeglumine.
BOPTA is a derivative of DTPA in which one terminal carboxyl group, –C(O)OH is replaced by -C–O–CH2C6H5. Thus gadobenic acid is closely related to gadopentetic acid. BOPTA itself was first synthesized in 1995. [1] In the "gadobenate" ion gadolinium ion is 9-coordinate with BOPTA acting as a 8-coordinating ligand. The ninth position is occupied by a water molecule, which exchanges rapidly with water molecules in the immediate vicinity of the strongly paramagnetic complex, providing a mechanism for MRI contrast enhancement. 139La NMR studies on the diamagnetic La-BOPTA2- complex suggest that the Gd complex maintains in solution the same kind of coordination as found, by X-ray crystallography, in the solid state for Gd-BOPTA disodium salt.[1]